PD40-02 TIM3 EXPRESSION ON TUMOR CELLS PREDICTS RESPONSE TO ANTI-PD-1 THERAPY FOR RENAL CANCER

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) II (PD40)1 Sep 2021PD40-02 TIM3 EXPRESSION ON TUMOR CELLS PREDICTS RESPONSE TO ANTI-PD-1 THERAPY FOR RENAL CANCER Renpei Kato, Takashi Tuyukubo, Daiki Ikarashi, Tomohiko Matsuura, Shigekatsu Maekawa, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, Kazuyuki Ishida, and Wataru Obara Renpei KatoRenpei Kato More articles by this author , Takashi TuyukuboTakashi Tuyukubo More articles by this author , Daiki IkarashiDaiki Ikarashi More articles by this author , Tomohiko MatsuuraTomohiko Matsuura More articles by this author , Shigekatsu MaekawaShigekatsu Maekawa More articles by this author , Yoichiro KatoYoichiro Kato More articles by this author , Mitsugu KanehiraMitsugu Kanehira More articles by this author , Ryo TakataRyo Takata More articles by this author , Kazuyuki IshidaKazuyuki Ishida More articles by this author , and Wataru ObaraWataru Obara More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002050.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: This study aimed to identify novel prognostic biomarker for advanced renal cell carcinoma (RCC) patients treated with anti-PD-1 therapy, using quantitative multi-immunofluorescence (IF) analysis of tumor immunity. METHODS: Twenty-five consecutive patients who had metastatic or unresectable RCC treated with anti-PD-1 therapy were studied. The patients were divided into a responder group (n=12) and a non-responder group (n=13). Quantitative multi-IF staining was performed on biopsy or surgical kidney samples using a panel of antibodies. Sections were scanned using a Mantra microscope, and the images were analyzed with inFormTM software. RESULTS: Responders had significantly higher rate of TIM3-positive tumor (100% versus 53.9%, p <0.01) than non-responders. Multi-IF analysis showed that TIM3 expression on tumor cells was most strongly related to response to anti-PD-1 therapy, while some of the known immune-related prognostic factors in RCC (CD45RO, FOXP3, VEGF, PD-L1, PD-L2, CD163) had no significant association. Patients with TIM3-positive tumor showed significantly longer overall survival (not reached median time versus 6.0 months, p <0.01) and progression-free survival (18.9 versus 1.1 months, p <0.01) than those with TIM3-negative tumor. Immunohistochemistry study using samples obtained after anti-PD-1 therapy showed infiltration of CD163 macrophages and release of HMGB1, a ligand of TIM3, in necrotic tumor area. CONCLUSIONS: Our study found clinical correlation between TIM3 expression on tumor cells and response to anti-PD-1 therapy. Further studies are warranted to verify whether TIM3 expression on tumor cells before systemic therapy predicts the efficacy of anti-PD-1 therapy for RCC in the clinical setting. Source of Funding: None of the funding sources had any role in the study © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e674-e674 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Renpei Kato More articles by this author Takashi Tuyukubo More articles by this author Daiki Ikarashi More articles by this author Tomohiko Matsuura More articles by this author Shigekatsu Maekawa More articles by this author Yoichiro Kato More articles by this author Mitsugu Kanehira More articles by this author Ryo Takata More articles by this author Kazuyuki Ishida More articles by this author Wataru Obara More articles by this author Expand All Advertisement Loading ...